BACKGROUND AND MISSION
Founded in Sweden in 1950, Ferring Pharmaceuticals is a research-driven biopharmaceutical company with its corporate headquarters in Saint-Prex, Switzerland. It researches, develops, manufactures and markets products in the fields of reproductive and sexual health, urology, gastroenterology, endocrinology and orthopaedics. The acquisition of Bio-Technology General in 2005 increased its capabilities in recombinant biotechnology. Ferring also undertakes research collaboration with scientific research institutes, universities and pharmaceutical and biotechnology companies around the world.

AREAS OF INTEREST
- Biopharmaceuticals
- Recombinant biotechnology
- Assisted reproductive technology in the treatment of infertility
- Peptide technology
- Drug delivery

HEALTH-RELATED ACTIVITIES
Ferring develops, manufactures and markets medicines to improve patients' health and quality of life. Its speciality is in the field of naturally occurring human peptides, resulting in treatments in the following key therapeutic areas: reproductive health, in particular, treatment of infertility, urology and gastroenterology. Ferring aims to produce new innovative drugs and to improve existing therapies by: focusing on novel peptide/hormone and protease genes, further developing peptide and peptidomimetic science and technology, and adapting existing peptide-based medications to meet specific medical needs.

GOVERNANCE AND STAFF
Ferring's marketing, medical services and sales teams operate from nearly 60 countries and employ more than 6'500 people throughout the world. The chairman of Ferring's 6-member board of directors is Frederik Pualsen, the son of the company's founder. Michel L. Pettigrew is the chief operating officer and president of the executive board.

FUNDING SOURCES AND BUDGET
Ferring's 2015 revenue totalled in EUR 1.8 billion.
PUBLICATIONS
For stories on different topics related to Ferring’s drugs, see:

Last update: 21.09.2019